1. Rutkowski P. Złośliwe nowotwory skóry. Via Medica, Gdańsk 2014.
  2. Didkowska J, Wojciechowska U, Olasek P. Nowotwory złośliwe w Polsce w 2017 roku. Cancer in Poland in 2017. Warszawa 2019.
  3. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. Dostępne na stronie http://onkologia.org.pl/raporty/ dostęp z dnia 05/04/2020.
  4. Jeffrey F. Scott, Meg R. Gerstenblith, editors. Noncutaneous Melanoma [Internet]. Brisbane (AU): Codon Publications; 2018 Mar. Chapter 1. Yde SS, Sjoegren P, Heje M, Stolle LB. Mucosal Melanoma: a Literature Review. Curr Oncol Rep. 2018 Mar 23;20(3):28. doi: 10.1007/s11912-018-0675-0. PMID: 29569184.
  5. Meleti M, Leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck 2008; 30:1543.;
  6. Rapini RP, Golitz LE, Greer RO Jr, et al. Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer 1985; 55:1543.
  7. Lotem M, Anteby S, Peretz T, et al. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol Oncol 2003; 88:45.
  8. Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Canc Netw 2012; 10:345.
  9. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664
  10. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Dec 1;30(12):1884-1901. doi: 10.1093/annonc/mdz411. PMID: 31566661
  11. Wouters MW, Michielin O, Bastiaannet E, et al. ECCO essential requirements for quality cancer care: Melanoma. Crit Rev Oncol Hematol.2018; 122: 164–178, doi: 10.1016/j.critrevonc.2017.12.020, indexed in Pubmed: 29458785.
  12. Michielin O, Akkooi Av, Ascierto PA, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019; 30(12): 1884–1901, doi: 10.1093/ annonc/mdz411.
  13. Gajda M, Kaminska-Winciorek G. Do not let to be late: overview ofreasons for melanoma delayed diagnosis. Asian Pac J Cancer Prev.2014; 15(9): 3873–3877, doi: 10.7314/apjcp.2014.15.9.3873, indexed in Pubmed: 24935566.
  14. Kamińska-Winciorek G, Placek W. The most common mistakes on dermatoscopy of melanocytic lesions. Postepy Dermatol Alergol. 2015; 32(1): 33–39, doi: 10.5114/pdia.2014.44029, indexed in Pubmed: 25821425.
  15. NCCN Guidelines. Cutaneous melanoma version 1.2021.
  16. Elder E, Massi D, Scolyer RA, et al. Classification of Skin Tumours 4th Edition. International Agency for Research on Cancer 2018.
  17. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Mod Pathol. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. 2018 Jan;31(1):24-38.
  18. Vanni I, Tanda ET, Spagnolo F, Andreotti V, Bruno W, Ghiorzo P. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Front Mol Biosci. 2020;7:113.
  19. Raghavan, S.S., Peternel, S., Mully, T.W. et al. Spitz melanoma is a distinct subset of spitzoid melanoma. Mod Pathol 33, 1122–1134 (2020).
  20. Giubellino A, Zhou Y (2019) Molecular Characterization of Spitz Tumors: An Approach to Improve Disease Diagnosis and Classification. J Mol Genet Med 13: 417.
  21. Hayward NK, Wilmott JS, Waddell N et al. Whole-genome landscapes of major melanoma subtypes. Nature 2017; 545(7653): 175–180
  22. Gershenwald JE, Scolyer RA, Hess KR. Melanoma of the skin. AJCC Cancer Staging Manual. Eight Edition. Springer 2017.
  23. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36): 6199–6206, doi: 10.1200/JCO.2009.23.4799, indexed in Pubmed: 19917835.
  24. Morton DL, Thompson JF, Cochran AJ, et al. MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014; 370(7): 599–609, doi: 10.1056/NEJMoa1310460, indexed in Pubmed: 24521106.
  25. Wong SL, Balch CM, Hurley P, et al. American Society of Clinical Oncology, Society of Surgical Oncology. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012; 30(23): 2912–2918, doi: 10.1200/JCO.2011.40.3519, indexed in Pubmed: 22778321.
  26. Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Keilholz U. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020 Nov;31(11):1449-1461. doi: 10.1016/j.annonc.2020.07.005. Epub 2020 Aug 4. PMID: 32763452.
  27. Nowecki ZI, Rutkowski P, Michej W. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol. 2008; 15(8): 2223–2234, doi: 10.1245/s10434-008-9965-3, indexed in Pubmed: 18506535.
  28. Faries M, Thompson J, Cochran A, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine. 2017; 376(23): 2211–2222, doi: 10.1056/nejmoa1613210.
  29. Leiter U, Stadler R, Mauch C, et al. German Dermatologic Cooperative Oncology Group (DeCOG). Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016; 17(6): 757–767, doi: 10.1016/S1470-2045(16)00141-8, indexed in Pubmed: 27161539.
  30. van Akkooi ACJ, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg. 2008; 248(6): 949–955, doi: 10.1097/SLA.0b013e31818fefe0, indexed in Pubmed: 19092339.
  31. Testori A, Rutkowski P, Marsden J, et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol. 2009; 20 Suppl 6: vi22– –vi29, doi: 10.1093/annonc/mdp257, indexed in Pubmed: 19617294.
  32. Mali B, Jarm T, Snoj M, et al. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol. 2013; 39(1): 4–16, doi: 10.1016/j.ejso.2012.08.016, indexed in Pubmed: 22980492.
  33. Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25): 2780–2788, doi: 10.1200/ JCO.2014.58.3377, indexed in Pubmed: 26014293.
  34. Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg 1970; 120:425.
  35. Smith HG, Bagwan I, Board RE, Capper S, Coupland SE, Glen J, Lalondrelle S, Mayberry A, Muneer A, Nugent K, Pathiraja P, Payne M, Peach H, Smith J, Westwell S, Wilson E, Rodwell S, Gore M, Turnbull N, Smith MJF. Ano-uro-genital mucosal melanoma UK national guidelines. Eur J Cancer. 2020 Aug;135:22-30. doi: 10.1016/j.ejca.2020.04.030. Epub 2020 Jun 9. PMID: 32531566
  36. McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol. 2008 Nov;44(11):1039-46. doi: 10.1016/j.oraloncology.2008.01.014. Epub 2008 Apr 8. PMID: 18396446
  37. Agrawal S, Kane JM 3rd, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009 Dec 15;115(24):5836-44. doi: 10.1002/cncr.24627. PMID: 19701906. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf dostęp 29.01.2021.
  38. Bullard KM, Tuttle TM, Rothenberger DA, Madoff RD, Baxter NN, Finne CO, Spencer MP. Surgical therapy for anorectal melanoma. J Am Coll Surg. 2003; 196:206–11. https://doi.org/10.1016/S1072-7515(02)01538-7.
  39. Kiran RP, Rottoli M, Pokala N, Fazio VW. Long-term outcomes after local excision and radical surgery for anal melanoma: data from a population database. Dis Colon Rectum. 2010; 53:402–08. https://doi.org/10.1007/ DCR.0b013e3181b71228.
  40. Malaguarnera G, Madeddu R, Catania VE, Bertino G, Morelli L, Perrotta RE, Drago F, Malaguarnera M, Latteri S. Anorectal mucosal melanoma. Oncotarget. 2018 Jan 2;9(9):8785-8800. doi: 10.18632/oncotarget.23835. PMID: 29492238; PMCID: PMC5823579.
  41. Lee AY, Berman RS. Management of Noncutaneous Melanomas. Surg Oncol Clin N Am. 2020 Jul;29(3):387-400. doi: 10.1016/j.soc.2020.02.004. PMID: 32482315.
  42. Pittaka, M.; Kardamakis, D.; Spyropoulou, D. Comparison of International Guidelines on Mucosal Melanoma of the Head and Neck: A Comprehensive Review of the Role of Radiation Therapy. In Vivo 2016, 30, 165–170.
  43. Eggermont AMM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol. 2007; 34(6): 509–515, doi: 10.1053/j.seminoncol.2007.09.003, indexed in Pubmed: 18083374.
  44. Sondak VK, Gonzalez RJ, Kudchadkar R. Adjuvant therapy for melanoma: a surgical perspective. Surg Oncol Clin N Am. 2011; 20(1): 105––114, doi: 10.1016/j.soc.2010.09.001, indexed in Pubmed: 21111961.
  45. Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016; 375(19): 1845–1855, doi: 10.1056/NEJMoa1611299, indexed in Pubmed: 27717298.
  46. Eggermont AMM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012; 48(2): 218–225, doi: 10.1016/j.ejca.2011.09.028, indexed in Pubmed: 22056637.
  47. Weber J, Mandala M, Del Vecchio M, et al. CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017; 377(19): 1824–1835, doi: 10.1056/ NEJMoa1709030, indexed in Pubmed: 28891423.
  48. Coens C, Suciu S, Chiarion-Sileni V, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015; 16(5): 522–530, doi: 10.1016/S1470-2045(15)70122-1, indexed in Pubmed: 25840693.
  49. Weber J, Mandalà M, Vecchio MD, et al. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). Journal of Clinical Oncology. 2018; 36(15_suppl): 9502–9502, doi: 10.1200/jco.2018.36.15_suppl.9502.
  50. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018; 378(19): 1789–1801, doi: 10.1056/NEJMoa1802357, indexed in Pubmed: 29658430.
  51. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol. 2020 Nov 20;38(33):3925-3936. doi: 10.1200/JCO.20.02110. Epub 2020 Sep 18. PMID: 32946353; PMCID: PMC7676886.
  52. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017; 377(19): 1813–1823, doi: 10.1056/NEJMoa1708539, indexed in Pubmed: 28891408.
  53. Hauschild A, Dummer R, Schadendorf D, et al. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. J Clin Oncol. 2018; 36(35): 3441–3449, doi: 10.1200/JCO.18.01219,indexed in Pubmed: 30343620.
  54. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma:a randomised trial. Lancet Oncol. 2012; 13(6): 589–597, doi: 10.1016/S1470-2045(12)70138-9, indexed in Pubmed: 22575589.
  55. Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma:rationale and indications. Oncology (Williston Park). 2004; 18(1):99–107; discussion 107, indexed in Pubmed: 14768409.
  56. Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph--node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015; 16(9): 1049–1060, doi: 10.1016/S1470-2045(15)00187-4, indexed in Pubmed:26206146.
  57. Rutkowski P, Kiprian D, Dudzisz-Śledź M, et al. Management of brain metastases in melanoma. Oncol Clin Pract. 2018; 14: 148–155, doi: 5603/ OCP.2018.0031.
  58. Rutkowski P, Kiprian D, Dudzisz-Śledź M, et al. Management of melanoma metastases in the brain. Nowotwory. Journal of Oncology. 2019; 69(3-4): 86–96, doi: 10.5603/njo.2019.0018.
  59. Fogarty G, Dolven-Jacobsen K, Morton R, et al. Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).Journal of Clinical Oncology. 2019; 37(15_suppl): 9500–9500, doi:10.1200/jco.2019.37.15_suppl.9500.
  60. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8): 711–723, doi: 10.1056/NEJMoa1003466, indexed in Pubmed: 20525992.
  61. Świtaj T, Wysocki P, Wojtukiewicz M, et al. Ipilimumab — postępy w terapii chorych na zaawansowanego czerniaka. Onkol Prakt Klin. 2011; 7: 231–245.
  62. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23): 7412–7420, doi: 10.1158/1078-0432.CCR-09-1624, indexed in Pubmed: 19934295.
  63. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372(4): 320––330, doi: 10.1056/NEJMoa1412082, indexed in Pubmed: 25399552.
  64. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4): 375–384, doi: 10.1016/S1470- 2045(15)70076-8, indexed in Pubmed: 25795410.
  65. Robert C, Schachter J, Long GV, et al. KEYNOTE-006 investigators, KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26): 2521–2532, doi: 10.1056/NEJMoa1503093, indexed in Pubmed: 25891173.
  66. Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Rutkowski P, Hassel JC, McNeil CM, Kalinka EA, Lebbé C, Charles J, Hernberg MM, Savage KJ, Chiarion-Sileni V, Mihalcioiu C, Mauch C, Arance A, Cognetti F, Ny L, Schmidt H, Schadendorf D, Gogas H, Zoco J, Re S, Ascierto PA, Atkinson V. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. J Clin Oncol. 2020 Nov 20;38(33):3937-3946. doi: 10.1200/JCO.20.00995. Epub 2020 Sep 30. PMID: 32997575; PMCID: PMC7676881.
  67. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1): 23–34.
  68. Robert C, Ribas A, Hamid O, et al. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018; 36(17): 1668–1674, doi: 10.1200/ JCO.2017.75.6270, indexed in Pubmed: 29283791.
  69. Wolchok J, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2017; 377(14): 1345–1356, doi: 10.1056/nejmoa1709684.
  70. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16): 1535–1546, doi: 10.1056/NEJMoa1910836, indexed in Pubmed: 31562797.
  71. Shoushtari, A.N.; Wagstaff, J.; Ascierto, P.A.; Butler, M.O.; Lao, C.D.; Marquez-Rodas, I.; Chiarion-Sileni, V.; Dummer, R.; Ferrucci, P.F.; Lorigan, P.; et al. CheckMate 067: Long-Term outcomes in patients with mucosal melanoma. J. Clin. Oncol. 2020, 38, 10019.
  72. Angelo SPD, Larkin J, Sosman JA, Lebb C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017; 35:226–35.
  73. Li J, Kan H, Zhao L, Sun Z, Bai C. Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review. Ther Adv Med Oncol. 2020 May 18; 12:1758835920922028. doi: 10.1177/1758835920922028. PMID: 32489431; PMCID: PMC7238311.
  74. Long G, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet Oncology. 2018; 19(5): 672–681, doi: 10.1016/s1470-2045(18)30139-6.
  75. Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018; 379(8): 722–730, doi: 10.1056/NEJMoa1805453, indexed in Pubmed: 30134131.
  76. Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507–2516, doi: 10.1056/NEJMoa1103782, indexed in Pubmed: 21639808.
  77. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839): 358–365, doi: 10.1016/S0140--6736(12)60868-X, indexed in Pubmed: 22735384.
  78. Flaherty KT, Robert C, Hersey P, et al. METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2): 107–114, doi: 10.1056/NEJMoa1203421, indexed in Pubmed: 22663011.
  79. Ascierto P, Berking C, Agarwala S, et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. Journal of Clinical Oncology. 2012; 30(15_suppl): 8511–8511, doi: 10.1200/jco.2012.30.15_suppl.8511.
  80. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372(1): 30–39, doi: 10.1056/NEJMoa1412690, indexed in Pubmed: 25399551.
  81. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametynib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; 386(9992): 444–451, doi: 10.1016/S0140-6736(15)60898-4, indexed in Pubmed: 26037941.
  82. Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016; 17(9): 1248–1260, doi: 10.1016/S1470--2045(16)30122-X, indexed in Pubmed: 27480103.
  83. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Annals of Oncology. 2016; 27: vi575, doi: 10.1093/annonc/mdw435.37.
  84. Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2018; 19(5): 603–615, doi: 10.1016/S1470-2045(18)30142-6, indexed in Pubmed: 29573941\
  85. Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018; 19(10): 1315–1327, doi: 10.1016/S1470-2045(18)30497-2, indexed in Pubmed: 30219628.
  86. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019; 381(7): 626–636, doi: 10.1056/NEJMoa1904059, indexed in Pubmed: 31166680.
  87. Schreuer M, Jansen Y, Planken S, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF-mutant melanoma: an open-label, single arm, dual--centre, phase 2 clinical trial. Lancet Oncol. 2017; 18(4): 464–472, doi: 10.1016/S1470-2045(17)30171-7, indexed in Pubmed: 28268064.
  88. Valpione S, Carlino M, Mangana J, et al. Re-challenge with BRAF- -directed treatment: A multi-institutional retrospective study. Journal of Clinical Oncology. 2017; 35(15_suppl): 9512–9512, doi: 10.1200/jco.2017.35.15_suppl.9512.
  89. Cybulska-Stopa B, Rogala P, Czarnecka A, et al. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. Melanoma Research. 2020: 1, doi: 10.1097/cmr.0000000000000662.
  90. Guo J, Si Lu, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011; 29(21): 2904–2909, doi: 10.1200/JCO.2010.33.9275, indexed in Pubmed: 21690468.
  91. Czarnecka AM, Teterycz P, Mariuk-Jarema A, et al. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. Target Oncol. 2019; 14(6): 729–742, doi: 10.1007/s11523-019-00688-8, indexed in Pubmed:31754963.
  92. Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020 Nov;31(11):1435-1448. doi: 10.1016/j.annonc.2020.07.004. Epub 2020 Aug 4. PMID: 32763453.
  93. Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, Yan Y, Huang KC, Uyei A, McNally V, McArthur GA, Ascierto PA. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 Jun 13;395(10240):1835-1844. doi: 10.1016/S0140-6736(20)30934-X. Erratum in: Lancet. 2020 Aug 15;396(10249):466. PMID: 32534646.
  94. Arié A, Yamamoto T. Lymphedema secondary to melanoma treatments: diagnosis, evaluation, and treatments. Glob Health Med. 2020 Aug 31;2(4):227-234. doi: 10.35772/ghm.2020.01022. PMID: 33330812; PMCID: PMC7731060.
  95. I.Malicka, K Siewierska w red M. Wożniewski: Fizjoterapia w onkologii PZWL 2020
  96. Campanholi, Larissa & Duprat, João & Fregnani, José. Analysis of physical therapy in patients who had radical lymphadenectomy for cutaneous melanoma. Applied Cancer Research. 2012;32(1):12-15.
  97. Gjorup CA, Groenvold M, Hendel HW, Dahlstroem K, Drzewiecki KT, Klausen TW, Hölmich LR. Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema. Eur J Cancer. 2017 Nov; 85:122-132. doi: 10.1016/j.ejca.2017.07.052. Epub 2017 Sep 15. PMID: 28918186.
  98. Gjorup CA, Hendel HW, Zerahn B, Dahlstroem K, Drzewiecki KT, Klausen TW, Hölmich LR. Volume and Tissue Composition Changes Measured with Dual-Energy X-Ray Absorptiometry in Melanoma-Related Limb Lymphedema. Lymphat Res Biol. 2017 Sep;15(3):274-283. doi: 10.1089/lrb.2017.0013. Epub 2017 Sep 8. PMID: 28885862.
  99. Jassem J, Duchnowska R, Kawecki A, et al. Badania kontrolne po leczeniu w najczęstszych nowotworach litych u dorosłych. Nowotwory. Journal of Oncology. 2014; 64(5): 415–435, doi: 10.5603/njo.2014.0070.
  100. Rutkowski P, Lugowska I. Follow-up in melanoma patients. Memo. 2014; 7(2): 83–86, doi: 10.1007/s12254-014-0151-y, indexed in Pubmed: 25089158.
  101. Kamposioras K., G. Pentheroudakis, D. Pectasides, N. Pavlidis, Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature, Critical Reviews in Oncology/Hematology, Volume 78, Issue 2, 2011, Pages 112-126. https://doi.org/10.1016/j.critrevonc.2010.04.007
  102. Rodrigues, M. et al. So close, yet so far: discrepancies between uveal and other melanomas. A position paper from UM Cure 2020. Cancers 11, e1032 (2019).
  103. Wojciechowska Urszula, Didkowska Joanna, Irmina Michałek, Paweł Olasek, Agata Ciuba. Nowotwory złośliwe w Polsce w 2018 roku. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. http://onkologia.org.pl/publikacje/
  104. Kaliki, S. & Shields, C. L. Uveal melanoma: Relatively rare but deadly cancer. Eye 31, 241–257 (2017). ////Singh, A. D., Turell, M. E. & Topham, A. K. Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology 118, 1881–1885, https://doi.org/10.1016/j.ophtha.2011.01.040 (2011).
  105. Virgili, G. et al. Incidence of Uveal Melanoma in Europe. Ophthalmology 114, https://doi.org/10.1016/j.ophtha.2007.01.032 (2007).
  106. Kivelä, T. The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Br J Ophthalmol 93, 1129–1131, https://doi.org/10.1136/bjo.2008.150292 (2009).
  107. Shields, C. L. et al. Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture. Eye 29, 1027–1035, https:// doi.org/10.1038/eye.2015.51 (2015).]
  108. Al-Jamal, R. T. et al. The pediatric choroidal and ciliary body melanoma study: A survey by the European Ophthalmic Oncology Group. Ophthalmology 123, 898–907, https://doi.org/10.1016/j.ophtha.2015.12.024 (2016).
  109. Kivelä T. Prevalence and epidemiology of ocular melanoma.In: Murray T, Boldt HC, eds. Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies. London: Future Science; 2014:21–38
  110. Żygulska-Mach H. Epidemiologia czerniaka oka. Współczesna Onkologia 1998;(8):226-227.
  111. Cabanis EEA, Bourgeois H, Iba-Zizen MT. Imagerie en ophtalmologie. Masson. Paris 1996, 486-502.
  112. Martine J. Jager, Carol L. Shields, Colleen M. Cebulla, Mohamed H. Abdel- Rahman, Hans E. Grossniklaus, Marc- Henri Stern, Richard D. Carvajal, Rubens N. Belfort, Renbing Jia, Jerry A. Shields and Bertil E. Damato. Uveal melanoma. Nature Reviews, Disease Primers 020 6:24. doi.org/10.1038/s4157-020-0158-0.
  113. Shields, C. L. et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch. Ophthalmol.127, 989–998 (2009).
  114. Berus T, Halon A, Markiewicz A, Orlowska-Heitzman J, Romanowska-Dixon B, Donizy P. Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma – A Comprehensive Review. Anticancer Res. 2017;37(12). ]
  115. McLean, I. W., Foster, W. D., Zimmerman, L. E. & Gamel, J. W. Modifications of Callender’s classificationof uveal melanoma at the Armed Forces Institute of Pathology. Am. J. Ophthalmol. 96, 502–509 (1983)
  116. Folberg, R. et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100, 1389–1398 (1993)
  117. Bronkhorst IHG and Jager MJ: Inflammation in uveal melanoma. Eye 27: 217-223, 2013
  118. Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330,1410–1413 (2010)].
  119. Shields, J. A. & Shields, C. L. Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens Lecture. Ophthalmology 122,414–428 (2015)
  120. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561–8.
  121. AJCC Ophthalmic Oncology Task Force. International validation of the American Joint Committee on Cancer’s 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 133, 376–383 (2015).
  122. Damato, E. M. & Damato, B. E. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2384 patients. Ophthalmology 119,1582–1589 (2012)
  123. Romanowska-Dixon B, Jakubowska B, Karska-Basta I, Kubicka Trząska A., Damato B. Uveal Tumors. Differential diagnosis of intraocular tumors. Edytorzy Romanowska- Dixon B. Jager MJ, Coupland S, Ocular Oncology, Copyright by PZWL Wydawnictwo Lekarskie, Warszawa 2020, str. 105-369
  124. Shields, J. A., Shields, C. L., Ehya, H., Eagle, R. C. & De Potter, P. Fine-needle aspiration biopsy of suspected intraocular tumors. The 1992 Urwick Lecture. Ophthalmology 100, 1677–1684 (1993)
  125. NCCN Guidelines. Uveal Melanoma. Version 3.2020
  126. Shields, C. L. et al. Choroidal nevus imaging features in 3,806 cases and risk factors for transformation into melanoma in 2,355 cases: the 2020 Taylor R. Smith and Victor T. Curtin Lecture. Retina 39, 1840–1851. (2018).
  127. Shields JA, Mashayekhi A, Ra S, Shields CL. Pseudomelanomas of the posterior uveal tract: the 2006 Taylor R. Smith Lecture. Retina 2005; 25(6): 767–771.
  128. Shields, C. L. et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106consecutive patients. Arch. Ophthalmol. 118,1219–1228 (2000).
  129. Collaborative Ocular Melanoma Study Group.Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology 108, 348–366 (2001).
  130. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124(12): 1684–1693.
  131. The American Brachytherapy Society – Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13: 1-14.
  132. Straatsma BR. Golden Jubilee Lecture. Randomised clinical trials of choroidal melanoma treatment. Indian J Ophthalmol. 2003;51:17–23.
  133. Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. III. Initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119:969–82.
  134. Collaborative Ocular Melanoma Study Group: Mortality in patients with small choroidal melanoma. COMS Report No.4. Arch Ophthalmol. 1997;115:886–93
  135. Gragoudas, E. S., Lane, A. M., Munzenrider, J., Egan, K. M. & Li, W. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans. Am. Ophthalmol. Soc. 100, 43–48 (2002).]
  136. Damato B. The role of eyewall resection in uveal melanoma management. Int Ophthalmol Clin 2006; 46(1): 81–93.
  137. Konstantinidis L, Groenewald C, Coupland SE, Damato B. Long-term outcome of primary endoresection of choroidal melanoma. Br J Ophthalmol 2014; 98(1): 82–85.
  138. Agnieszka Kubicka-Trząska, Krzysztof Morawski, Anna Markiewicz, Bożena Romanowska-Dixon. Prevention and treatment of the toxic tumour syndrome following primary proton beam therapy of choroidal melanomas. Arch Med Sci Civil Dis 2020; 5: e22–e28. DOI: https://doi.org/10.5114/amscd.2020.94102
  139. Turkoglu, E. B., Pointdujour-Lim, R., Mashayekhi, A.& Shields, C. L. Photodynamic therapy as primary treatment for small choroidal melanoma. Retina 39,1319–1325 (2018).
  140. Rundle, P. Treatment of posterior uveal melanoma with multi-dose photodynamic therapy. Br. J. Ophthalmol.98, 494–497 (2014).
  141. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019 Dec;29(6):561-568. doi: 10.1097/CMR.0000000000000575. PMID: 30664106; PMCID: PMC6887637.
  142. G. Fiorentini, C. Aliberti, A. Del Conte, M. Tilli, S. Rossi, P. Ballardini, G. Turrisi, G. Benea: Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. 2009;23(1):131-7
  143. Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, Glover MS, Simien R, Diab A, Hwu P, Carter BW, Patel SP. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol. 2020 Oct 30:JCO2000605. doi: 10.1200/JCO.20.00605. Epub ahead of print. PMID: 33125309.
  144. Piulats JM, Espinosa E, de la Cruz Merino L, Varela M, Alonso Carrión L, Martín-Algarra S, López Castro R, Curiel T, Rodríguez-Abreu D, Redrado M, Gomà M, Rullán AJ, Calvo González A, Berrocal-Jaime A. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021 Jan 8:JCO2000550. doi: 10.1200/JCO.20.00550. Epub ahead of print. PMID: 33417511.
  145. Rodriguez-Vidal C, Fernandez-Diaz D, Fernandez-Marta B, Lago-Baameiro N, Pardo M, Silva P, Paniagua L, Blanco-Teijeiro MJ, Piñeiro A, Bande M. Treatment of Metastatic Uveal Melanoma: Systematic Review. Cancers (Basel). 2020 Sep 8;12(9):2557. doi: 10.3390/cancers12092557. PMID: 32911759; PMCID: PMC7565536.
  146. 64MO – Sacco JJ, Carvajal R, Butler MO, et al. A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM). ESMO Immuno-Oncology Virtual Congress 2020 (9-12 December 2020).
  147. Shields, J. A. & Shields, C. L. Intraocular Tumors: An Atlas and Textbook 3rd edn (Wolters Kluwer, 2015).
  148. Barker, C. A. & Salama, A. K. New NCCN guidelines for uveal melanoma and treatment of recurrent or progressive distant metastatic melanoma. J. Natl Compr. Cancer Netw. 16, 646–650 (2018).
  149. Damato, B. in Retinal Vascular Disease (eds Joussen, A. M., Gardner, T. W., Kirchhof, B. & Ryan, S. J.)582–591 (Springer, 2007)
  150. Paul T. Finger, MD; Kimberly Chin, OD Anti–Vascular Endothelial Growth Factor Bevacizumab (Avastin) for Radiation Retinopathy. Arch Ophthalmol. 2007;125:751-756]]
  151. Nathan, P. et al. Uveal melanoma UK national guidelines. Eur. J. Cancer 51, 2404–2412 (2015).
  152. Elyse S Blum, Jessica Yang, Kimberly M Komatsubara, Richard D Carvajal. Clinical Management of Uveal and Conjunctival Melanoma. Oncology (Williston Park) 2016 Jan;30(1):29-32, 34-43, 48.
  153. McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000-7.
  154. Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011;118:389-95. e1-2.
  155. Missotten GS, Keijser S, De Keizer RJ, De Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci. 2005;46:75-82.
  156. Shields CL, Shields JA, Gunduz K, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118:1497-507.
  157. Wong JR, Nanji AA, Galor A, Karp CL. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol. 2014;9:185-204.
  158. Paridaens AD, McCartney AC, Minassian DC, Hungerford JL. Orbital exenteration in 95 cases of primary conjunctival malignant melanoma. Br J Ophthalmol. 1994;78:520-8.
  159. Norregaard JC, Gerner N, Jensen OA, Prause JU. Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol. 1996;234:569-72.
  160. Finger PT, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol. 1998;82:476-9.
  161. Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience. Graefes Arch Clin Exp Ophthalmol. 2005;243:1108-14.
  162. Demirci H, McCormick SA, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol. 2000;118:885-91.
  163. Ditta LC, Shildkrot Y, Wilson MW. Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. Ophthalmology. 2011;118:1754-9.
  164. Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol. 2010;94:1316-21.
  165. Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol. 2006;90:819-22.
  166. Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol. 2008;145:124-9.
  167. Herold TR, Hintschich C. Interferon alpha for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol. 2010;248:111-5.
  168. Esmaeli B, Wang X, Youssef A, Gershenwald JE. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology. 2001;108:2101-5.
  169. Tuomaala S, Kivela T. Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy. Ophthalmology. 2004;111:816.
  170. Walewski J., Dziurda D., et. al. Consensus on methods of development of clinical practice guidelines in oncology under the auspices of Maria Sklodowska-Curie National Research Institute of Oncology and the Agency for Health Technology Assessment and Tariff System. Nowotwory. Journal of Oncology 2022;72(1):44-50
  171. Facciolà A, Venanzi Rullo E, Ceccarelli M, D'Andrea F, Coco M, Micali C, Cacopardo B, Marino A, Cannavò SP, Di Rosa M, Condorelli F, Pellicanò GF, Guarneri C, Nunnari G. Malignant melanoma in HIV: Epidemiology, pathogenesis, and management. Dermatol Ther. 2020 Jan;33(1):e13180. doi: 10.1111/dth.13180. Epub 2019 Dec 9. PMID: 31770477.
  172. Agozzino M, Moscarella E, Babino G, Caccavale S, Piccolo V, Argenziano G. The use of in vivo reflectance confocal microscopy for the diagnosis of melanoma. Expert Rev Anticancer Ther. 2019 May;19(5):413-421. doi: 10.1080/14737140.2019.1593829. Epub 2019 Mar 28. PMID: 30869538.
  173. http://www.pol-pat.pl/pliki/files/standardy_pdf/1.2_czerniak.pdf
  174. Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12.
  175. Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 Mar 31:S0140-6736(22)00562-1. doi: 10.1016/S0140-6736(22)00562-1. Epub ahead of print. PMID: 35367007.
  176. Reinhard Dummer, M.D., Axel Hauschild, M.D., Mario Santinami, M.D., Victoria Atkinson, M.D., Mario Mandalà, M.D., John M. Kirkwood, M.D., Vanna Chiarion Sileni, M.D., James Larkin, M.D., Ph.D., Marta Nyakas, M.D., Caroline Dutriaux, M.D., Andrew Haydon, M.B., B.S., Ph.D., Caroline Robert, M.D., Ph.D., Laurent Mortier, M.D., Ph.D., Jacob Schachter, M.D., Thierry Lesimple, M.D., Ruth Plummer, M.D., Kohinoor Dasgupta, Ph.D., Eduard Gasal, M.D., Monique Tan, M.D., Georgina V. Long, M.B., B.S., Ph.D., and Dirk Schadendorf, M.D. et. al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. September 17, 2020. N Engl J Med 2020; 383:1139-1148. DOI: 10.1056/NEJMoa2005493
  177. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefford, J.D. Wolchok, P. Hersey, R. Joseph, J.S. Weber, R. Dronca, T.C. Mitchell, A. Patnaik, H.M. Zarour, A.M. Joshua, Q. Zhao, E. Jensen, S. Ahsan, N. Ibrahim, A. Ribas, Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001, Annals of Oncology, Volume 30, Issue 4, 2019, Pages 582-588,ISSN 0923-7534,https://doi.org/10.1093/annonc/mdz011.
  178. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24. PMID: 34818112; PMCID: PMC8718224.
  179. Paolo A. Ascierto, Brigitte Dréno, James Larkin, Antoni Ribas, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Jessie Hsu, Surai Jones, Haocheng Li, Edward McKenna, Athina Voulgari, Grant A. McArthur; 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin Cancer Res 1 October 2021; 27 (19): 5225–5235. https://doi.org/10.1158/1078-0432.CCR-21-0809
  180. Paolo A. Ascierto, Reinhard Dummer, Helen J. Gogas, Keith T. Flaherty, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Jan Willem B. de Groot, Carmen Loquai, Ashwin Gollerkeri, Michael D. Pickard, Caroline Robert, Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma, European Journal of Cancer, Volume 126, 2020, Pages 33-44, https://doi.org/10.1016/j.ejca.2019.11.016.
  181. Ascierto PA, Mandala M, Ferrucci PF I wsp. LBA40 - SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized studyAnnals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741
  182. Atkins MB, Lee SJ, Chmielowski B, et al: DREAMseq: A phase III trial—ECOG-ACRIN EA6134. ASCO Plenary Series. Abstract 356154. Presented November 16, 2021.
  183. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. PMID: 34986285.
  184. Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S; IMCgp100-202 Investigators. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485. PMID: 34551229.
  185. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13. PMID: 29028110; PMCID: PMC5978683.
Strona korzysta z plików cookies w celu realizacji usług i zgodnie z Polityką Plików Cookies. Możesz określić warunki przechowywania lub dostępu do plików cookies w Twojej przeglądarce.